26TH COMPREHENSIVE CANCER CENTER

DEVELOPMENTAL THERAPEUTICS SYMPOSIUM

The goals of this activity are for participants to examine synthesized data from completed studies, discuss the novel investigational agents available in ongoing clinical trials, and describe the rationale for and results of studies that include novel agents for the treatment of patients with advanced cancer. This information will enable them to use new treatments available to cancer patients appropriately, support current and future oncology clinical trials, and become stronger leaders in oncology research. In sum, this program will convey information on how to better implement precision medicine in oncologic care, leading to better outcomes for patients with cancer.

AT THE FOREFRONT
UChicagoMedicine
Comprehensive Cancer Center

ACCREDITED BY UNIVERSITY OF CHICAGO

AT THE FOREFRONT
UChicagoMedicine
Comprehensive Cancer Center

The University of Chicago
Comprehensive Cancer Center
5841 S. Maryland Avenue
Chicago, IL 60637

Follow us on Twitter: @UChicagoCME

SCAN OR VISIT TO REGISTER TODAY!
www.UofCDevelopmentalTherapeuticsSymposium.org
QUESTIONS? Contact Meeting Achievements at
Leslie@meetingachievements.com Or 219.465.1115

26TH COMPREHENSIVE CANCER CENTER
DEVELOPMENTAL THERAPEUTICS SYMPOSIUM

SAVE THE DATE:
MAY 12, 2023

JOIN US IN-PERSON!
THE GLEACHER CENTER
CHICAGO, ILLINOIS

COURSE DIRECTORS

Walter M. Stadler, MD
Course Co-Director
University of Chicago Medicine

Olatoyosi Odenike, MD
Course Co-Director
University of Chicago Medicine

AT THE FOREFRONT
UChicagoMedicine
Comprehensive Cancer Center

PROGRAM INFORMATION

TARGET AUDIENCE:

This activity is designed for physicians and other healthcare professionals who diagnose, screen, and treat patients with cancer.

LEARNING OBJECTIVES:

After this activity, participants will be able to:

- State the clinical effects of novel immunotherapeutic agents, including but not limited to novel checkpoint inhibitors, bispecific antibodies, and novel cellular therapies;
- Assess the status of and developmental pathway for antibody-drug conjugates in solid and hematologic tumors;
- Discuss the current science related to radioligand therapy and available agents;
- Cite the relevant pharmacologic and biologic effects of novel anti-cancer agents through the use of blood and tissue samples as well as standard and novel imaging approaches, including novel PET tracer imaging and circulating tumor DNA assays;
- Identify how to assess patient suitability for participation in ongoing and upcoming cancer clinical trials and projects;
- Discuss advances in the use of systemic therapies for cancer, including those targeting specific molecular alterations such as DNA repair mutations, specific chromosomal translocations, and tyrosine kinase mutations.

ACCREDITATION AND CREDIT DESIGNATION STATEMENT:

PHYSICIAN CREDIT: The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Chicago Pritzker School of Medicine designates this live activity for a maximum of **5.25** *AMA PRA Category 1 Credits*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSING CREDIT: University of Chicago Medicine is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Participants who successfully complete the entire activity and complete an evaluation form will earn **5.25** contact hours.

AMERICAN BOARD OF INTERNAL MEDICINE MOC PART II CREDIT: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to **5.25** MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

OTHER HEALTHCARE PROFESSIONAL CREDIT: Other healthcare professionals will receive a Certificate of Participation. For information on the applicability and acceptance of Certificates of Participation for educational activities certified for *AMA PRA Category 1 Credit*™ from organizations accredited by the ACCME, please consult your professional licensing board.

26TH COMPREHENSIVE CANCER CENTER

DEVELOPMENTAL THERAPEUTICS SYMPOSIUM

AGENDA: MAY 12, 2023

8:15 am **REGISTRATION/ BREAKFAST/ EXHIBITS**

8:45 am **WELCOME**

SESSION 1
Moderator Walter Stadler, MD

The Current Landscape of Novel Therapeutics in Breast Cancer
Nan Chen, MD

New Treatments for Advanced NSCLC
Marina Garassino, MD

New Frontiers in the Incorporation of Novel Therapeutics and Biomarkers in Head and Neck Cancer
Ari Rosenberg, MD

10:05 am **BREAK/EXHIBITS**

10:25 am **SESSION 2**
Moderator Toyosi Odenike, MD

Fine-Tuning BCMA-Directed and Alternative Immunotherapies in Multiple Myeloma
Benjamin Derman, MD

Updates in Targeted Therapies in Gastrointestinal Cancers
Ardaman Shergill, MD

Optimizing Cellular Therapy in Lymphoma
Peter Riedell, MD

Immunotherapy for Myeloid Malignancies–Are We There Yet?
Hongtao Liu, MD, PhD

12:05 pm **LUNCH/ LUNCHTIME BREAKOUTS**

12:20 pm ***CONCURRENT LUNCHTIME BREAKOUTS**
Moderator Walter Stadler, MD

Regulatory and Pragmatic Issues for Running Cancer and Clinical Trials
Livia Szeto
Sara Moellering
Lauren Wall

Debate with Dr. Alex Pearson: "Be it resolved that AI tools will eliminate the need for detailed somatic sequencing for determination of therapeutic targets"
Alex Pearson, MD, PhD
Melissa Pessin, MD, PhD

1:05 pm **BREAK/EXHIBITS**

1:20 pm **SESSION 3**
Moderator Toyosi Odenike, MD

Technological Advances in Genitourinary Cancer Therapy
Randy Sweis, MD

Beyond PARP Inhibitors: Recent Updates and Evolving Novel Therapies for Gynecologic Cancers
Katherine Kurnit, MD, MPH

Adoptive Cell Therapy for Solid Tumors
Dan Olson, MD

2:35 pm **CLOSING REMARKS**
Toyosi Odenike, MD
Walter Stadler, MD

2:40 pm **ADJOURN**

2:40 pm **POST-CONFERENCE RECEPTION**
For Trainees (Residents & Fellows) Developing a Career in Clinical Research
Walter Stadler, MD
Toyosi Odenike, MD

REGISTER TODAY: UofCDevelopmentalTherapeuticsSymposium.org